Indications for FASENRA:
As add-on maintenance treatment of severe asthma in patients ≥12yrs old, and with an eosinophilic phenotype.
Limitations of Use:
Not for treating other eosinophilic conditions. Not for relief of acute bronchospasm or status asthmaticus.
Give by SC inj into upper arm, thigh, or abdomen. 30mg once every 4 weeks for the first 3 doses, then once every 8 weeks thereafter.
Not for treating acute asthma symptoms or exacerbations. Discontinue if hypersensitivity reactions occur. Treat pre-existing helminth infections before initiating therapy; discontinue Fasenra if treatment-resistant infection occurs while on therapy until resolves. Avoid abrupt discontinuation of systemic or inhaled corticosteroids; reduce dose gradually upon Fasenra initiation, if appropriate. Reduction may be associated with systemic withdrawal symptoms and/or unmask previously suppressed conditions. Pregnancy. Nursing mothers.
Headache, pharyngitis, pyrexia, hypersensitivity reactions.
Half-life: ~15.5 days.
Single-dose prefilled syringe—1; Single-dose autoinjector (pen)—1